How much profit has Innoviva made this year?
Innoviva has made 33.82 M USD this year.
Innoviva Net Income 2024
Innoviva Net Income
33.82 M USD
Ticker
INVA
ISIN
US45781M1018
WKN
A2AC9U
In 2024, Innoviva's profit amounted to 33.82 M USD, a -81.18% increase from the 179.72 M USD profit recorded in the previous year.
The Innoviva Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | 147.4 |
| 2028e | 117.41 |
| 2027e | 85.51 |
| 2026e | 83.27 |
| 2025e | 72.74 |
| 2024e | 33.82 |
| 2023 | 179.72 |
| 2022 | 213.9 |
| 2021 | 265.9 |
| 2020 | 224.4 |
| 2019 | 157.3 |
| 2018 | 395.1 |
| 2017 | 134.1 |
| 2016 | 59.5 |
| 2015 | -18.8 |
| 2014 | -168.5 |
| 2013 | -170.7 |
| 2012 | -18.5 |
| 2011 | -115.3 |
| 2010 | -83.9 |
| 2009 | -85.3 |
| 2008 | -93.6 |
| 2007 | -160 |
| 2006 | -166 |
| 2005 | -143.2 |
| 2004 | -102.7 |
Innoviva Revenue, EBIT, Net Income US45781M1018 · A2AC9U
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Innoviva, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Innoviva from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Innoviva’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Innoviva. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Innoviva’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Innoviva’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Innoviva’s growth potential.
Innoviva Revenue, EBIT and net profit per share
| Date | Innoviva Revenue | Innoviva EBIT | Innoviva Net Income |
|---|---|---|---|
| 2029e | 563.65 M undefined | 0 undefined | 147.4 M undefined |
| 2028e | 459.82 M undefined | 205.22 M undefined | 117.41 M undefined |
| 2027e | 377.6 M undefined | 162.18 M undefined | 85.51 M undefined |
| 2026e | 376.25 M undefined | 128.32 M undefined | 83.27 M undefined |
| 2025e | 347.35 M undefined | 115.28 M undefined | 72.74 M undefined |
| 2024e | 345.38 M undefined | 103.23 M undefined | 33.82 M undefined |
| 2023 | 310.46 M undefined | 113.89 M undefined | 179.72 M undefined |
| 2022 | 331.3 M undefined | 207 M undefined | 213.9 M undefined |
| 2021 | 391.9 M undefined | 375.1 M undefined | 265.9 M undefined |
| 2020 | 336.8 M undefined | 321.1 M undefined | 224.4 M undefined |
| 2019 | 261 M undefined | 246.4 M undefined | 157.3 M undefined |
| 2018 | 261 M undefined | 238.3 M undefined | 395.1 M undefined |
| 2017 | 217.2 M undefined | 183.6 M undefined | 134.1 M undefined |
| 2016 | 133.6 M undefined | 109 M undefined | 59.5 M undefined |
| 2015 | 53.9 M undefined | 31.6 M undefined | -18.8 M undefined |
| 2014 | 8.4 M undefined | -33.9 M undefined | -168.5 M undefined |
| 2013 | 4.5 M undefined | -28.8 M undefined | -170.7 M undefined |
| 2012 | 135.8 M undefined | -13 M undefined | -18.5 M undefined |
| 2011 | 24.5 M undefined | -109.7 M undefined | -115.3 M undefined |
| 2010 | 24.2 M undefined | -78.3 M undefined | -83.9 M undefined |
| 2009 | 24.4 M undefined | -80.3 M undefined | -85.3 M undefined |
| 2008 | 23.1 M undefined | -87.8 M undefined | -93.6 M undefined |
| 2007 | 22 M undefined | -168.6 M undefined | -160 M undefined |
| 2006 | 19.6 M undefined | -179.2 M undefined | -166 M undefined |
| 2005 | 12.1 M undefined | -149.6 M undefined | -143.2 M undefined |
| 2004 | 8.9 M undefined | -106.4 M undefined | -102.7 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 8.9 M USD | -106.4 M USD | -102.7 M USD |
| 2005 | 12.1 M USD | -149.6 M USD | -143.2 M USD |
| 2006 | 19.6 M USD | -179.2 M USD | -166 M USD |
| 2007 | 22 M USD | -168.6 M USD | -160 M USD |
| 2008 | 23.1 M USD | -87.8 M USD | -93.6 M USD |
| 2009 | 24.4 M USD | -80.3 M USD | -85.3 M USD |
| 2010 | 24.2 M USD | -78.3 M USD | -83.9 M USD |
| 2011 | 24.5 M USD | -109.7 M USD | -115.3 M USD |
| 2012 | 135.8 M USD | -13 M USD | -18.5 M USD |
| 2013 | 4.5 M USD | -28.8 M USD | -170.7 M USD |
| 2014 | 8.4 M USD | -33.9 M USD | -168.5 M USD |
| 2015 | 53.9 M USD | 31.6 M USD | -18.8 M USD |
| 2016 | 133.6 M USD | 109 M USD | 59.5 M USD |
| 2017 | 217.2 M USD | 183.6 M USD | 134.1 M USD |
| 2018 | 261 M USD | 238.3 M USD | 395.1 M USD |
| 2019 | 261 M USD | 246.4 M USD | 157.3 M USD |
| 2020 | 336.8 M USD | 321.1 M USD | 224.4 M USD |
| 2021 | 391.9 M USD | 375.1 M USD | 265.9 M USD |
| 2022 | 331.3 M USD | 207 M USD | 213.9 M USD |
| 2023 | 310.46 M USD | 113.89 M USD | 179.72 M USD |
| 2024e | 345.38 M USD | 103.23 M USD | 33.82 M USD |
| 2025e | 347.35 M USD | 115.28 M USD | 72.74 M USD |
| 2026e | 376.25 M USD | 128.32 M USD | 83.27 M USD |
| 2027e | 377.6 M USD | 162.18 M USD | 85.51 M USD |
| 2028e | 459.82 M USD | 205.22 M USD | 117.41 M USD |
| 2029e | 563.65 M USD | 0 USD | 147.4 M USD |
Innoviva stock margins US45781M1018 · A2AC9U
The Innoviva margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Innoviva. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Innoviva.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Innoviva's sales revenue. A higher gross margin percentage indicates that the Innoviva retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Innoviva's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Innoviva's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Innoviva's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Innoviva. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Innoviva's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Innoviva Margin History
| Innoviva Gross margin | Innoviva Profit margin | Innoviva EBIT margin | Innoviva Profit margin |
|---|---|---|---|
| 2029e | 86.27 % | 0 % | 26.15 % |
| 2028e | 86.27 % | 44.63 % | 25.53 % |
| 2027e | 86.27 % | 42.95 % | 22.64 % |
| 2026e | 86.27 % | 34.1 % | 22.13 % |
| 2025e | 86.27 % | 33.19 % | 20.94 % |
| 2024e | 86.27 % | 29.89 % | 9.79 % |
| 2023 | 86.27 % | 36.68 % | 57.89 % |
| 2022 | 95.83 % | 62.48 % | 64.56 % |
| 2021 | 86.27 % | 95.71 % | 67.85 % |
| 2020 | 86.27 % | 95.34 % | 66.63 % |
| 2019 | 86.27 % | 94.41 % | 60.27 % |
| 2018 | 86.27 % | 91.3 % | 151.38 % |
| 2017 | 86.27 % | 84.53 % | 61.74 % |
| 2016 | 86.27 % | 81.59 % | 44.54 % |
| 2015 | 86.27 % | 58.63 % | -34.88 % |
| 2014 | 86.27 % | -403.57 % | -2,005.95 % |
| 2013 | 86.27 % | -640 % | -3,793.33 % |
| 2012 | 86.27 % | -9.57 % | -13.62 % |
| 2011 | 86.27 % | -447.76 % | -470.61 % |
| 2010 | 86.27 % | -323.55 % | -346.69 % |
| 2009 | 86.27 % | -329.1 % | -349.59 % |
| 2008 | 86.27 % | -380.09 % | -405.19 % |
| 2007 | 86.27 % | -766.36 % | -727.27 % |
| 2006 | 86.27 % | -914.29 % | -846.94 % |
| 2005 | 86.27 % | -1,236.36 % | -1,183.47 % |
| 2004 | 86.27 % | -1,195.51 % | -1,153.93 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 86.27 % | -1,195.51 % | -1,153.93 % |
| 2005 | 86.27 % | -1,236.36 % | -1,183.47 % |
| 2006 | 86.27 % | -914.29 % | -846.94 % |
| 2007 | 86.27 % | -766.36 % | -727.27 % |
| 2008 | 86.27 % | -380.09 % | -405.19 % |
| 2009 | 86.27 % | -329.1 % | -349.59 % |
| 2010 | 86.27 % | -323.55 % | -346.69 % |
| 2011 | 86.27 % | -447.76 % | -470.61 % |
| 2012 | 86.27 % | -9.57 % | -13.62 % |
| 2013 | 86.27 % | -640 % | -3,793.33 % |
| 2014 | 86.27 % | -403.57 % | -2,005.95 % |
| 2015 | 86.27 % | 58.63 % | -34.88 % |
| 2016 | 86.27 % | 81.59 % | 44.54 % |
| 2017 | 86.27 % | 84.53 % | 61.74 % |
| 2018 | 86.27 % | 91.3 % | 151.38 % |
| 2019 | 86.27 % | 94.41 % | 60.27 % |
| 2020 | 86.27 % | 95.34 % | 66.63 % |
| 2021 | 86.27 % | 95.71 % | 67.85 % |
| 2022 | 95.83 % | 62.48 % | 64.56 % |
| 2023 | 86.27 % | 36.68 % | 57.89 % |
| 2024e | 86.27 % | 29.89 % | 9.79 % |
| 2025e | 86.27 % | 33.19 % | 20.94 % |
| 2026e | 86.27 % | 34.1 % | 22.13 % |
| 2027e | 86.27 % | 42.95 % | 22.64 % |
| 2028e | 86.27 % | 44.63 % | 25.53 % |
| 2029e | 86.27 % | 0 % | 26.15 % |
Innoviva Aktienanalyse
What does Innoviva do?
Innoviva Inc - An innovative story Innoviva Inc is a US-based company specializing in the development and marketing of therapy and diagnostic products for respiratory diseases. The company was founded in 1996 under the name Theravance Inc and was renamed Innoviva Inc in 2016. The story of Innoviva Inc began with the goal of developing innovative therapies for chronic respiratory diseases. Over the years, the company expanded and diversified its product portfolio. Today, Innoviva Inc is a leading provider of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Business model of Innoviva Inc The business model of Innoviva Inc is based on the development of products for the treatment of respiratory diseases and collaboration with other pharmaceutical and biotech companies. The company licenses its products to partner companies, which distribute them in the market. This way, Innoviva Inc generates revenue from licensing fees and milestone payments. Divisions of Innoviva Inc Innoviva Inc is divided into three divisions: development, licensing, and financing. The development division is responsible for researching and developing new therapy and diagnostic products. The company works closely with other pharmaceutical and biotech companies in this regard. The licensing division is responsible for licensing products to partner companies. This includes negotiating license agreements and conducting clinical trials. The financing division of Innoviva Inc is responsible for raising external capital. This includes issuing bonds and seeking investment. Products of Innoviva Inc Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. These include: - RELVAR®/BREO® (Fluticasone furoate/Vilanterol) for the treatment of COPD and asthma - ANORO® (Umeclidinium bromide/Vilanterol) for the treatment of COPD - TRELEGY® (Fluticasone furoate/Umeclidinium bromide/Vilanterol) for the treatment of COPD These products have been developed by Innoviva Inc and are licensed to partner companies for distribution. Innoviva Inc is an innovative company specializing in the development and marketing of products for the treatment of respiratory diseases. The business model is based on the development of products and licensing them to partner companies. Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. Innoviva ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Innoviva's Profit Margins
The profit margins of Innoviva represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Innoviva's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Innoviva's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Innoviva's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Innoviva’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Innoviva stock
How has the profit developed compared to last year?
The profit has increased by -81.18% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Innoviva publish its earnings?
Innoviva publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Innoviva?
The profits of Innoviva are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Innoviva?
You can learn more about the earnings of Innoviva by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Innoviva pay?
Over the past 12 months, Innoviva paid a dividend of 0.75 USD . This corresponds to a dividend yield of about 3.79 %. For the coming 12 months, Innoviva is expected to pay a dividend of 0 USD.
What is the dividend yield of Innoviva?
The current dividend yield of Innoviva is 3.79 %.
When does Innoviva pay dividends?
Innoviva pays a quarterly dividend. This is distributed in the months of December, April, July, October.
How secure is the dividend of Innoviva?
Innoviva paid dividends every year for the past 0 years.
What is the dividend of Innoviva?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Innoviva located?
Innoviva is assigned to the 'Health' sector.
Wann musste ich die Aktien von Innoviva kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Innoviva from 9/30/2015 amounting to 0.25 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2015.
When did Innoviva pay the last dividend?
The last dividend was paid out on 9/30/2015.
What was the dividend of Innoviva in the year 2023?
In the year 2023, Innoviva distributed 0 USD as dividends.
In which currency does Innoviva pay out the dividend?
The dividends of Innoviva are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Innoviva stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Innoviva
Our stock analysis for Innoviva Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innoviva Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
